Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

http://www.wikidata.org/entity/Q41508527

about

Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.An Evaluation of Systemic Vancomycin Dosing in Obese Patients New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy Performance of a divided-load intravenous vancomycin dosing strategy for obese patients.Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients.Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.No role for patient body weight on renal function assessment for drug dosing.Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.Identification of Risk Factors for Initial Elevated Vancomyin Trough Concentrations.Pharmacokinetics of vancomycin in patients with different renal function levels

P2860

Q35762761-18E37D1D-2017-4742-A034-9E5751F16593 Q36405861-3CC33F27-FE34-48DB-8C0F-43D02B19609F Q37120168-15DAF413-D061-4327-9E06-EAD7A48F1497 Q37283031-C736A237-27FE-48CA-B5B4-3CF5FBFFE8BA Q38488889-B2BD3602-5493-4899-8603-D8143D3E2425 Q38882052-E963D283-DE36-45B1-BBA2-1FE95407D7AC Q40067964-529C7FF2-06BA-46AA-8D04-BB083BA0A023 Q40569211-2C490ACE-E223-4D45-9812-D23E0B16DCBF Q47223964-884B0085-2ADA-49C6-BB69-541F23C302AB Q47275031-72CF8E39-6793-46F7-B13A-80948CD7AB46 Q55265388-13796B3B-B011-4C9B-B621-F21A0A2AEBA0 Q58691019-94B7F9A1-128F-4D2D-9CEE-CC8DD4584506

P2860

Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

http://www.wikidata.org/entity/Q41508527

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacokinetics of vancomycin ...... phylococcus aureus infections.

@en

type

label

Pharmacokinetics of vancomycin ...... phylococcus aureus infections.

@en

prefLabel

Pharmacokinetics of vancomycin ...... phylococcus aureus infections.

@en

P1433

Q41508527-BB3D531D-7ED0-43D2-9D61-0EA68C546E93

P1476

Q41508527-FAF58584-7F22-4021-9CEA-42F9ECC6B363

P2093

Q41508527-19A2A103-161B-44EF-BB7E-0614BEE85E32

Q41508527-B1B83BA3-36A2-48C0-BCC4-AFED7E44EA24

Q41508527-E0007C69-9509-4080-813A-51017BDB5669

P2860

Q41508527-04DA0681-812F-4716-B443-9A3A88C9D7DF

Q41508527-0584AF14-0AD9-4409-8D92-9D00580EF6F2

Q41508527-0A8C3F17-A20B-466D-A048-95DB2DDB9723

Q41508527-19150473-4993-4E17-B2DC-80CFA3925AA5

Q41508527-1969E526-842F-4513-9DF8-44029ACAED2E

Q41508527-260D07C0-1024-4FFD-AF37-93E3E173C696

Q41508527-31F225AC-02BC-4275-939D-559041F54BE9

Q41508527-38A01A43-8319-4A7F-B86D-E8DE86AF9E7D

Q41508527-3FF71C20-8363-4E92-B57A-77C1B3DDA43C

Q41508527-4094A4B5-1A1C-44F0-A3C1-E8273A8E7E16

P304

Q41508527-CFEEF0E8-0AF2-4D9B-9A36-B54161B4CC75

P31

Q41508527-64BD2DFC-47FC-45B6-A125-F2D3BB1B6E76

P356

Q41508527-6939BB2E-161C-47BD-8D47-903DCB798DE0

P407

Q41508527-240689D4-81D4-4A16-AE8F-80CAAF4A85B4

P433

Q41508527-D766BBBD-B43A-43AA-80F6-571CD5F6ECAF

P478

Q41508527-A86A8A8F-06D9-44BE-A90F-CF8054C92CB2

P577

Q41508527-4DB539D3-636C-4053-BD29-98873F54C2FA

P698

Q41508527-DE372506-7C6B-46F5-9E30-82AB26A29EB1

P921

Q41508527-1E517C0B-143A-4ADB-B5E4-98882602197C

Q41508527-B7A4614B-412A-48FF-A984-FFA8BAA1FB08

P356

P1433

Pharmacotherapy

P1476

Pharmacokinetics of vancomycin ...... phylococcus aureus infections.

@en

P2093

Eyob D Adane

http://www.w3.org/2001/XMLSchema#string

Firas Koura

http://www.w3.org/2001/XMLSchema#string

Michael Herald

http://www.w3.org/2001/XMLSchema#string

P2860

Obesity and infection

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

Prediction of creatinine clearance from serum creatinine

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Vancomycin: a 50-year reassessment.

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.

Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

P304

127-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1531

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25644478

http://www.w3.org/2001/XMLSchema#string

P921

diagnostic test